Foghorn Therapeutics reported revenue of $16.07M and net income of -$7.19M for the quarter ended Jun 2026, up 112.7% year over year. This income statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||||
| Revenue | 0.04M | 0.71M | 3.92M | 4.49M | 6.63M | 4.18M | 5.31M | 5.60M | 17.48M | 5.77M | 5.05M | 6.89M | 7.81M | 2.86M | 5.95M | 7.56M | 8.15M | 9.25M | 3.27M | 16.07M | ||||||||
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 20.49M | 22.46M | 24.51M | 25.97M | 26.93M | 28.21M | 29.98M | 29.25M | 26.25M | 24.20M | 25.53M | 23.80M | 24.69M | 20.51M | 21.63M | 21.79M | 20.00M | 22.05M | 18.26M | 18.52M | ||||||||
| Selling, General & AdministrativeSG&A | 5.81M | 6.33M | 7.22M | 7.70M | 7.96M | 7.86M | 8.64M | 8.40M | 8.31M | 7.02M | 7.71M | 7.33M | 6.97M | 6.35M | 7.24M | 6.86M | 6.65M | 6.80M | 6.58M | 6.35M | ||||||||
| Other Operating ExpensesOther Opex | 2.40M | 4.28M | ||||||||||||||||||||||||||
| Operating ExpensesOpex | 26.30M | 28.80M | 31.72M | 33.68M | 34.89M | 36.07M | 38.63M | 37.65M | 34.56M | 31.23M | 33.24M | 33.52M | 31.66M | 26.86M | 28.86M | 28.65M | 26.65M | 33.12M | 24.84M | 24.88M | ||||||||
| Operating IncomeOp. Inc | -26.26M | -28.08M | -27.80M | -29.19M | -28.26M | -31.89M | -33.32M | -32.05M | -17.08M | -25.46M | -28.19M | -26.63M | -23.85M | -24.00M | -22.91M | -21.10M | -18.50M | -23.88M | -21.57M | -8.80M | ||||||||
| EBIT | -26.26M | -28.08M | -27.80M | -29.19M | -28.26M | -31.89M | -33.32M | -32.05M | -17.08M | -25.46M | -28.19M | -26.63M | -23.85M | -24.00M | -22.91M | -21.10M | -18.50M | -23.88M | -21.57M | -8.80M | ||||||||
| Non-operating items | ||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.50M | 0.43M | ||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.23M | 1.23M | 1.84M | 2.38M | 2.67M | 2.79M | 2.75M | 2.66M | 2.44M | 2.87M | 3.50M | 3.10M | 2.69M | 2.31M | 2.03M | 1.71M | 1.74M | 1.61M | ||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.68M | -1.20M | 0.66M | 0.65M | 0.65M | 0.62M | 0.72M | 0.71M | 0.72M | 0.68M | 0.74M | 0.78M | 1.24M | 1.41M | 1.39M | 0.85M | 0.62M | 0.50M | -0.04M | 0.01M | ||||||||
| Non Operating IncomeNon Op. Inc. | 0.18M | -1.06M | 0.89M | 1.88M | 2.49M | 3.00M | 3.39M | 3.50M | 3.47M | 3.34M | 3.18M | 3.65M | 4.73M | 4.50M | 4.08M | 3.16M | 2.65M | 2.21M | 1.70M | 1.61M | ||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -26.76M | -28.51M | -26.91M | -27.31M | -25.77M | -28.89M | -29.93M | -28.55M | -13.61M | -22.12M | -25.02M | -22.98M | -19.12M | -19.50M | -20.22M | -18.79M | -16.47M | -22.17M | -19.83M | -7.20M | ||||||||
| Tax ProvisionsTaxes | 0.56M | 0.94M | 0.74M | 1.99M | ||||||||||||||||||||||||
| Profit After TaxPAT | -26.08M | -29.12M | -26.91M | -27.31M | -27.44M | -28.01M | -30.49M | -29.49M | -14.35M | -24.11M | -25.02M | -22.98M | -19.12M | -19.50M | -18.83M | -17.99M | -15.85M | -21.66M | -19.88M | -7.19M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -26.76M | -28.51M | -26.91M | -27.31M | -25.77M | -28.89M | -30.49M | -29.49M | -14.35M | -24.11M | -25.02M | -22.98M | -19.12M | -19.50M | -20.22M | -18.79M | -16.47M | -22.17M | -19.83M | -7.20M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -26.76M | -28.51M | -26.91M | -27.31M | -25.77M | -28.89M | -30.49M | -29.49M | -14.35M | -24.11M | -25.02M | -22.98M | -19.12M | -19.50M | -20.22M | -18.79M | -16.47M | -22.17M | -19.83M | -7.20M | ||||||||
| Income towards Parent CompanyParent Net Inc | -26.76M | -28.51M | -26.91M | -27.31M | -25.77M | -28.89M | -30.49M | -29.49M | -14.35M | -24.11M | -25.02M | -22.98M | -19.12M | -19.50M | -20.22M | -18.79M | -16.47M | -22.17M | -19.83M | -7.20M | ||||||||
| Net Income towards Common StockholdersNet Income | -26.76M | -28.51M | -26.91M | -27.31M | -25.77M | -28.89M | -30.49M | -29.49M | -14.35M | -24.11M | -25.02M | -22.98M | -19.12M | -19.50M | -20.22M | -18.79M | -16.47M | -22.17M | -19.83M | -7.20M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -0.72 | -0.77 | -0.65 | -0.66 | -0.62 | -0.69 | -0.73 | -0.70 | -0.34 | -0.57 | -0.59 | -0.45 | -0.31 | -0.36 | -0.32 | -0.30 | -0.26 | -0.35 | -0.29 | -0.10 | ||||||||
| EPS (Diluted) | -0.72 | -0.77 | -0.65 | -0.66 | -0.62 | -0.69 | -0.73 | -0.70 | -0.34 | -0.57 | -0.59 | -0.45 | -0.31 | -0.36 | -0.32 | -0.30 | -0.26 | -0.35 | -0.29 | -0.10 | ||||||||
| Shares Outstanding | 36.97M | 37.17M | 41.37M | 41.52M | 41.67M | 41.59M | 41.81M | 41.83M | 42.03M | 41.97M | 42.43M | 51.58M | 62.60M | 54.90M | 62.85M | 62.98M | 63.03M | 62.98M | 69.54M | 70.63M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 36.97M | 37.17M | 41.37M | 41.52M | 41.67M | 41.59M | 41.81M | 41.83M | 42.03M | 41.97M | 42.43M | 51.58M | 62.60M | 54.90M | 62.85M | 62.98M | 63.03M | 62.98M | 69.54M | 70.63M | ||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 37.04M | 41.30M | 41.43M | 41.63M | 41.80M | 41.80M | 41.82M | 41.85M | 42.22M | 42.28M | 42.59M | 55.33M | 55.59M | 55.59M | 55.72M | 55.80M | 56.54M | 56.66M | 58.71M | 58.71M | ||||||||
| EBITDA | -26.26M | -28.08M | -27.80M | -29.19M | -28.26M | -31.89M | -33.32M | -32.05M | -17.08M | -25.46M | -28.19M | -26.63M | -23.85M | -24.00M | -22.91M | -21.10M | -18.50M | -23.88M | -21.57M | -8.80M | ||||||||
| Interest ExpensesInt Expense | 0.50M | 0.43M | ||||||||||||||||||||||||||
| Tax Rate | -1.87% | -3.30% | -5.42% | -8.98% |